drugset / Trial / NCT05970510

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

NCT05970510

Phase 3 Completed 555 enrolled Luye Pharma Group Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.

Timeline

Start
2023-08-04
Primary completion
2025-07-31
Completion
2025-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Toludesvenlafaxine Small molecule 80 mg Oral
Subject Toludesvenlafaxine Small molecule 160 mg Oral